Drug Profile
CM 2489
Alternative Names: CCI; CM-2489; CRAC channel inhibitor - CalciMedicaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator CalciMedica
- Class Antipsoriatics; Small molecules
- Mechanism of Action Immunosuppressants; ORAI1 protein inhibitors; STIM1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Plaque psoriasis
Most Recent Events
- 17 Nov 2016 Discontinued - Phase-I for Plaque psoriasis in USA (PO) before November 2016 (CalciMedica's website, November 2016)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Plaque-psoriasis in USA (PO)
- 17 Feb 2011 Phase-I clinical trials in Plaque psoriasis (in volunteers) in USA (PO)